Work

Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden

Year: 2021

Type: article

Study design: Observational Study

Abstract: This case-control study examines the risk of severe COVID-19 infection in individuals with multiple sclerosis who were receiving rituximab.

Source: JAMA Network Open

DOI: 10.1001/jamanetworkopen.2021.36697

Authors: Kyla A. McKay, Fredrik Piehl, Simon Englund, Anna He, Annette Langer-Gould, Jan Hillert, Thomas Frisell

Institutions: Karolinska University Hospital, Karolinska Institutet, Stockholm Health Care Services, Los Angeles Medical Center

Language: English

Topic: Multiple Sclerosis Research Studies

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,000

Funder: Patient-Centered Outcomes Research Institute

Award: G185083703

OpenAlex ID: W3215838965

FWCI: 1.667

Cites: 9

Cited by: 11

Related to: 10